Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Status:
Enrolling by invitation

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT)

Phase 3

Albireo